<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2204245184
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLAN 10 MG FILM-COATED  TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLANZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        217.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zolan&trade; contains the active substance olanzapine. Zolan&trade; belongs to a group of<br />medicines called antipsychotics and is used to treat the following conditions:<br />&bull; Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things<br />which are not there, mistaken beliefs, unusual suspiciousness, and becoming<br />withdrawn. People with this disease may also feel depressed, anxious or tense.<br />&bull; Moderate to severe manic episodes, a condition with symptoms of excitement or<br />euphoria.<br />Olanzapine has been shown to prevent recurrence of these symptoms in patients with<br />bipolar disorder whose manic episode has responded to olanzapine treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Zolan&trade;<br />&bull; If you are allergic (hypersensitive) to olanzapine or any of the other ingredients of<br />this medicine (listed in section 6). An allergic reaction may be recognised as a rash,<br />itching, a swollen face, swollen lips or shortness of breath. If this has happened to<br />you, tell your doctor.<br />&bull; If you have been previously diagnosed with eye problems such as certain kinds of<br />glaucoma (increased pressure in the eye).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before you take Zolan&trade;.<br />&bull; The use of Zolan&trade; in elderly patients with dementia is not recommended as it may<br />have serious side effects.<br />&bull; Medicines of this type may cause unusual movements mainly of the face or tongue.<br />If this happens after you have been given Zolan&trade; tell your doctor.<br />&bull; Very rarely, medicines of this type cause a combination of fever, faster breathing,<br />sweating, muscle stiffness and drowsiness or sleepiness. If this happens, contact your<br />doctor at once.<br />&bull; Weight gain has been seen in patients taking Zolan&trade;. You and your doctor should<br />check your weight regularly. Consider referral to a dietician or help with a diet plan if<br />necessary.<br />&bull; High blood sugar and high levels of fat (triglycerides and cholesterol) have been<br />seen in patients taking Zolan&trade;. Your doctor should do blood tests to check blood<br />sugar and certain fat levels before you start taking Zolan&trade; and regularly during<br />treatment.<br />&bull; Tell the doctor if you or someone else in your family has a history of blood clots, as<br />medicines like these have been associated with the formation of blood clots.<br />If you suffer from any of the following illnesses tell your doctor as soon as possible:<br />&bull; Stroke or &ldquo;mini&rdquo; stroke (temporary symptoms of stroke)<br />&bull; Parkinson&rsquo;s disease<br />&bull; Prostate problems<br />&bull; A blocked intestine (Paralytic ileus)<br />&bull; Liver or kidney disease<br />&bull; Blood disorders<br />&bull; Heart disease<br />&bull; Diabetes<br />&bull; Seizures<br />&bull; If you know that you may have salt depletion as a result of prolonged severe<br />diarrhoea and vomiting (being sick) or usage of diuretics (water tablets).<br />If you suffer from dementia, you or your carer/relative should tell your doctor if you<br />have ever had a stroke or &ldquo;mini&rdquo; stroke.<br />As a routine precaution, if you are over 65 years your blood pressure may be<br />monitored by your doctor.<br />Children and adolescents<br />Zolan&trade; is not for patients who are under 18 years.<br />Other medicines and Zolan&trade;<br />Only take other medicines while you are on Zolan&trade; if your doctor tells you that you<br />can. You might feel drowsy if Zolan&trade; is taken in combination with antidepressants<br />or medicines taken for anxiety or to help you sleep (tranquillisers).<br />Tell your doctor if you are taking, have recently taken or might take any other<br />medicines. In particular, tell your doctor if you are taking:<br />&bull; medicines for Parkinson&rsquo;s disease.<br />&bull; carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an<br />antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your<br />Zolan&trade; dose.<br />Zolan&trade; with alcohol<br />Do not drink any alcohol if you have been given Zolan&trade; as together with alcohol it<br />may make you feel drowsy.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to<br />have a baby, ask your doctor for advice before taking this medicine. You should not<br />be given this medicine when breast-feeding, as small amounts of Zolan&trade; can pass<br />into breast milk.<br />The following symptoms may occur in newborn babies, of mothers that have used<br />Zolan&trade; in the last trimester (last three months of their pregnancy): shaking, muscle<br />stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in<br />feeding. If your baby develops any of these symptoms you may need to contact your<br />doctor.<br />Driving and using machines<br />There is a risk of feeling drowsy when you are given Zolan&trade;. If this happens do not<br />drive or operate any tools or machines. Tell your doctor.<br />Zolan&trade; contains lactose<br />If you have been told by your doctor that you have an intolerance to some sugars,<br />contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your<br />doctor or pharmacist if you are not sure.<br />Your doctor will tell you how many Zolan&trade; tablets to take and how long you should<br />continue to take them. The daily dose of Zolan&trade; is between 5 mg and 20 mg. Consult<br />your doctor if your symptoms return but do not stop taking Zolan&trade; unless your doctor<br />tells you to.<br />You should take your Zolan&trade; tablets once a day following the advice of your doctor.<br />Try to take your tablets at the same time each day. It does not matter whether you<br />take them with or without food. Zolan&trade; coated tablets are for oral use. You should<br />swallow the Zolan&trade; tablets whole with water.<br />If you take more Zolan&trade; than you should<br />Patients who have taken more Zolan&trade; than they should have experienced the<br />following symptoms:<br />rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual<br />movements (especially of the face or tongue) and reduced level of consciousness.<br />Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination<br />of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness,<br />slowing of the breathing rate, aspiration, high blood pressure or low blood pressure,<br />abnormal rhythms of the heart. Contact your doctor or hospital straight away if<br />you experience any of the above symptoms. Show the doctor your pack of tablets.<br />If you forget to take Zolan&trade;<br />Take your tablets as soon as you remember. Do not take two doses in one day.<br />If you stop taking Zolan&trade;<br />Do not stop taking your tablets just because you feel better. It is important that you<br />carry on taking Zolan&trade; for as long as your doctor tells you.<br />If you suddenly stop taking Zolan&trade;, symptoms such as sweating, unable to sleep,<br />tremor, anxiety or nausea and vomiting might occur. Your doctor may suggest you to<br />reduce the dose gradually before stopping treatment.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets<br />them.<br />Tell your doctor immediately if you have:<br />&bull; unusual movement (a common side effect that may affect up to 1 in 10 people)<br />mainly of the face or tongue;<br />&bull; blood clots in the veins (an uncommon side effect that may affect up to 1 in 100<br />people) especially in the legs (symptoms include swelling, pain, and redness in the<br />leg), which may travel through blood vessels to the lungs causing chest pain and<br />difficulty in breathing. If you notice any of these symptoms seek medical advice<br />immediately;<br />&bull; a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness<br />or sleepiness (the frequency of this side effect cannot be estimated from the available<br />data).<br />Very common side effects (may affect more than 1 in 10 people) include weight<br />gain; sleepiness; and increases in levels of prolactin in the blood. In the early stages<br />of treatment, some people may feel dizzy or faint (with a slow heart rate), especially<br />when getting up from a lying or sitting position. This will usually pass on its own but<br />if it does not, tell your doctor.<br />Common side effects (may affect up to 1 in 10 people) include changes in the levels<br />of some blood cells, circulating fats and early in treatment, temporary increases in<br />liver enzymes; increases in the level of sugars in the blood and urine; increases in<br />levels of uric acid and creatine phosphokinase in the blood; feeling more hungry;<br />dizziness; restlessness; tremor; unusual movements(dyskinesias); constipation; dry<br />mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling<br />of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as<br />decreased libido in males and females or erectile dysfunction in males.<br />Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity<br />(e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of<br />diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine)<br />or coma; seizures, usually associated with a history of seizures (epilepsy); muscle<br />stiffness or spasms (including eye movements); problems with speech; slow heart<br />rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory<br />loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss;<br />absence or decrease in menstrual periods; and changes in breasts in males and<br />females such as an abnormal production of breast milk or abnormal growth.<br />Rare side effects (may affect up to 1 in 1000 people) include lowering of normal<br />body temperature; abnormal rhythms of the heart; sudden unexplained death;<br />inflammation of the pancreas causing severe stomach pain, fever and sickness; liver<br />disease appearing as yellowing of the skin and white parts of the eyes; muscle<br />disease presenting as unexplained aches and pains; and prolonged and/or painful<br />erection.<br />Very rare side effects include serious allergic reactions such as Drug Reaction with<br />Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as flu-like<br />symptoms with a rash on the face and then with an extended rash, high temperature,<br />enlarged lymph nodes, increased levels of liver enzymes seen on blood tests and an<br />increase in a type of white blood cells (eosinophilia).<br />While taking olanzapine, elderly patients with dementia may suffer from stroke,<br />pneumonia, urinary incontinence, falls, extreme tiredness, visual hallucinations, a<br />rise in body temperature, redness of the skin and have trouble walking. Some fatal<br />cases have been reported in this particular group of patients.<br />In patients with Parkinson&#39;s disease Zolan&trade; may worsen the symptoms.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or nurse. This includes any possible<br />side effects not listed in this leaflet.<br />By reporting side effects you can help provide more information on the safety of this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30 &ordm;C.<br />Do not use this medicine after the expiry date (&quot;EXP&quot;) which is stated on the carton.<br />Store in the original package in order to protect from light and moisture.<br />Medicines should not be disposed of via wastewater or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. These measures will<br />help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Zolan&trade; contains<br />The active substance is:<br />Zolan&trade; 5 mg: Each film coated tablet contains 5 mg of Olanzapine.<br />Zolan&trade; 10 mg: Each film coated tablet contains 10 mg of Olanzapine.<br />The other ingredients are:<br />Core: Lactose Monohydrate, Microcrystalline Cellulose, Crospovidone, Magnesium<br />stearate.<br />Coating: Opadry White OY-B-28920 [Polyvinyl alcohol partially hydrolyzed,<br />Titanium dioxide (E171), Talc, Lecithin soya (E322), Xanthan gum (E415)]</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Zolan™ looks like and contents of the pack:
Zolan™ 5 mg: White coloured, round, biconvex, film coated tablets, debossed with
“JP AB” on one side and Plain on other side.
Zolan™ 10 mg: White coloured, round, biconvex, film coated tablets, debossed with
“JP 147” on one side and Plain on other side.
Zolan™ film coated tablets available in 5 mg and 10 mg tablets in boxes of 30 tablets
each.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co., Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111,<br />Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 03/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>1. ما هو زولان&trade; و فيم يُستخدم</p><p>&nbsp;</p><p>يحتوي زولان&trade; على المادة الفعالة أولانزابين. ينتمي زولان&trade; إلى مجموعة أدوية تُسمى مضادات الذهان ويستخدم لعلاج الحالات التَّالية:</p><p>&bull; الفُصَام هو مرض له أعراض مثل رؤية أشياء أو سماع أصوات أو الشعور بأشياء غير موجودة وتكوين معتقدات خاطئة وارتياب غير معتاد وانعزال المرء. وقد يشعر الأشخاص الذين يعانون من هذا المرض بالاكتئاب أو القلق أو التوتر.</p><p>&bull; نوبات الهوس التي تتراوح بين المتوسطة والشديدة، وهي حالة تكون مصحوبة بأعراض إثارة أو نشوة.</p><p>&nbsp;</p><p>أثُبِتَ أن أولانزابين يمنع عودة هذه الأعراض بالنسبة للمرضى الذين يعانون من اضْطِّراب ثنائي القطب ممن استجابت نوبات الهوس لديهم للعلاج بأولانزابين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>2. ما تحتاج إلى معرفته قبل تناوُل زولان&trade;</p><p>&nbsp;</p><p>لا تتناول زولان&trade; في الحالات الآتية:</p><p>&bull; إذا كنت تعاني من حساسية (فرط حساسية) تجاه أولانزابين أو أيٍّ مكون من المكونات الأخرى الداخلة في تركيب هذا الدواء (المدرجة في القسم 6). قد تظهر الحساسية على شكل طفح جلدي أو حكة أو تورم الوجه أو تورم الشفتين أو ضيق التنفس. إذا تعرضت لهذه الأعراض، فأبلغ طبيبك.</p><p>&bull; إذا كان قد سبق تشخيصك بأنك تعاني من مشاكل بالعين مثل أنواع معينة من المياه الزرقاء &quot;الجلوكوما&quot; (ارتفاع الضغط داخل العين).</p><p>&nbsp;</p><p>تحذيرات واحتياطات</p><p>تحدث إلى طبيبك أو الصيدلي قبل تناول زولان&trade;.</p><p>&bull; لا يُنصح باستخدام زولان&trade; للمرضى من كبار السن المصابين بالخرف، إذ إنه قد يكون له آثار جانبية خطيرة.</p><p>&bull; قد يُؤدي العلاج بالأدوية من هذا النوع إلى حدوث حركات غير معتادة في الوجه أو اللسان بشكل أساسي. إذا تعرضت لهذه الأعراض بعد تناول زولان&trade;، فأبلغ طبيبك.</p><p>&bull; في حالات نادرة جدًّا: قد يُؤدي العلاج بمثل هذه الأدوية إلى حدوث مزيج من الحمى وسرعة التنفس والتَّعرق وتصلب العضلات والنعاس أو الرغبة في النوم. إذا تعرضت لهذه الأعراض، فاتصل بطبيبك على الفور.</p><p>&bull; قد لُوَحظ زيادة في وزن المرضى الذين يتناولون زولان&trade;. يجب أن تقوم أنت وطبيبك بقياس وزنك بشكل منتظم. يُنصح بالتفكير في زيارة أخصائي تغذية أو الحصول على مساعدة في وضع نظام غذائي خاص، إذا دعت الحاجة إلى ذلك.</p><p>&bull; لوحظ ارتفاع في مستويات السكر بالدَّم وارتفاع مستويات الدهون (الدهون ثلاثية الجليسريد و الكولسترول) لدى المرضى الذين يتناولون زولان&trade;. يجب أن يقوم طبيبك بإجراء فحوصات دم لك للتحقق من مستويات السكر في الدَّم ومستويات دهون معينة قبل أن تبدأ في تناول زولان&trade;، ويستمر بإجراء هذه الفحوصات بصفة منتظمة أثناء العلاج.</p><p>&bull; أخبر طبيبك إذا كان لديك أو لدى أحد الأشخاص في عائلتك تاريخ سابق من الإصابة بجلطات الدَّم؛ حيث أن استعمال مثل هذه الأدوية قد ارتبط بتكوُّن جلطات الدَّم.</p><p>&nbsp;</p><p>أبلغ طبيبك بأسرع وقت ممكن، إذا كنت تعاني من أي مرض من الأمراض التَّالية:</p><p>&bull; سكتة دماغية أو حالة إصابة صغيرة بسكتة دماغية (أعراض مؤقتة لسكتة دماغية).</p><p>&bull; الشلل الرعاشي (مرض باركنسون).</p><p>&bull; مشاكل بالبروستاتا.</p><p>&bull; انسداد الأمعاء (شلل الأمعاء).</p><p>&bull; أمراض بالكبد أو الكلى.</p><p>&bull; اضطرابات الدم.</p><p>&bull; مرض بالقلب.</p><p>&bull; مرض السُّكري.</p><p>&bull; نوبات تشنُّج.</p><p>&bull; إذا كنت تعلم أنك قد تكون مصابًا بعدم توفر الملح الناجم عن فترات طويلة من الإسهال أو القيء الشديدين (الإعياء) أو استخدام مدرات البول (أقراص الماء).</p><p>&nbsp;</p><p>إذا كنت تعاني من الخرف، فيجب عليك أو على من يرعاك/أفراد عائلتك إخبار طبيبك إذا كنا قد سبق وعانيت من سكتة دماغية أو حالة إصابة صغرى بسكتة دماغية.</p><p>&nbsp;</p><p>إذا كان عمرك يتجاوز 65 عامًا، فقد يقوم طبيبك بمراقبة ضغط الدَّم لديك كإجراء احترازي روتيني.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p>زولان&trade; غير مخصص للمرضى الذين تقل أعمارهم عن 18 عامًا.</p><p>&nbsp;</p><p>تناول الأدوية الأخرى مع زولان&trade;</p><p>لا تتناول أدوية أخرى أثناء العلاج بزولان&trade; ما لم يخبرك طبيبك بذلك. قد تشعر بنعاس في حالة تناول زولان&trade; بمصاحبة مضادات الاكتئاب أو الأدوية التي تستخدم في علاج القلق أو المساعدة على النوم (مهدئات).</p><p>أخبر طبيبك إذا كنت تتناول أو قد تناولت مؤخرًا أو قد تتناول أية أدوية أخرى. أخبر طبيبك على وجه الخصوص، إذا كنت تتناول أي من الأدوية التالية:</p><p>&bull; الأدوية التي تُستخدم لعلاج مرض الشلل الرعاش.</p><p>&bull; كاربامازيبين (دواء مُضاد للصرع ومُثبت للحالة المزاجيَّة) أو فلوفوكسامين (دواء مضاد للاكتئاب) أو سيبروفلوكساسين (مضاد حيوي)، فقد يكون من الضروري تعديل جرعتك من زولان&trade;.</p><p>&nbsp;</p><p>تناوُل زولان&trade; مع الكحوليات</p><p>لا تشرب أي كحوليات إذا وُصِف لك زولان&trade;؛ لأن تناوله مع الكحوليات قد يجعلك تشعر بالنعاس.</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p>إذا كنتِ حاملًا أو مرضعًا أو تعتقدين أنكِ حامل أو تخططين للحمل، فاستشيري طبيبكِ قبل تناوُل هذا الدَّواء. يُحظر وصف هذا الدواء للسيدات اللاتي يمارسن الرضاعة الطبيعية؛ لأنه قد تمر كميات قليلة من زولان&trade; إلى لبن الأم.</p><p>قد تحدث الأعراض التالية لدى الأطفال حديثي الولادة لأمهات قد استخدمن زولان&trade; خلال الأشهر الثلاث الأخيرة من حَمْلهن: ارتعاش، وتصلب العضلات و/أو ضعفها ونعاس وهياج ومشاكل بالتنفس وصعوبة في التَّغذية. إذا أُصيب طفلك بأيٍّ من هذه الأعراض فقد تحتاجين إلى الاتصال بطبيبك.</p><p>&nbsp;</p><p>القيادة واستخدام الآلات</p><p>قد تتعرض لخطر شعورك بالنعاس عند تناول زولان&trade;. إذا حدث لك ذلك، فتجنب القيادة، أو استخدام أية أدوات أو آلات. أبلغ طبيبك.</p><p>&nbsp;</p><p>يحتوي زولان&trade; على سكر اللاكتوز</p><p>إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاستشره قبل تناوُل هذا المستحضر الدَّوائي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>3. كيفية تناوُل زولان&trade;</p><p>&nbsp;</p><p>تناول هذا الدَّواء دائمًا كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًا من كيفية التناوُل.</p><p>سيخبرك طبيبك بعدد الأقراص التي يجب عليك تناولها من زولان&trade; و بالمدة التي ستستمر في تناول العقار خلالها. تتراوح الجرعة اليومية من زولان&trade; بين 5 ملجم و 20 ملجم.</p><p>استشر طبيبك إذا عادت إليك الأعراض ولكن لا تتوقف عن تناول زولان&trade;، ما لم يخبرك طبيبك بذلك.</p><p>يجب أن تتناول الأقراص المحددة لك من زولان&trade; مرة واحدة يوميًّا بعد استشارة طبيبك. حاول أن تتناول الأقراص في نفس الوقت من كل يوم. لا يهم تناول الأقراص مع الطعام أو دونه.</p><p>أقراص زولان&trade; المغلفة مخصصة للتناول عن طريق الفم. يجب عليك ابتلاع القرص كاملًا مع الماء.</p><p>&nbsp;</p><p>إذا تناولت كمية أكثر مما يجب من زولان&trade;</p><p>عانى المرضى الذين تناولوا كمية أكثر مما يجب من زولان&trade; من الأعراض التالية:</p><p>سرعة ضربات القلب وهِياج/ عدوانية ومشاكل في النطق وحركات غير معتادة (خاصةً في الوجه أو اللسان) وانخفاض مستوى الوعي. قد تتضمن الأعراض الأخرى: ارتباك حاد ونوبات تشنُّج (صرع) وغيبوبة ومزيج من الحمى وتسرع التنفس وتعرق وتصلب العضلات والنعاس أو الرغبة في النوم وتباطؤ معدل التنفس، رشف، ارتفاع ضغط الدم أو انخفاض ضغط الدَّم، نظم قلبي غير طبيعي. إذا تعرضت لأي من الأعراض المذكورة أعلاه، فاتصل بطبيبك أو المستشفى على الفور.</p><p>قدم إلى طبيبك عبوة الأقراص الخاصة بك.</p><p>&nbsp;</p><p>إذا نسيت تناول زولان&trade;</p><p>تناول الأقراص المحددة لك بمجرد تذكرها. لا تتناول جرعتين في يوم واحد.</p><p>&nbsp;</p><p>إذا توقفت عن تناوُل زولان&trade;</p><p>لا تتوقف عن تناول الأقراص المحددة لك لمجرد أنك تشعر بتحسن. من المهم أن تستمر في تناوُل</p><p>زولان&trade; طوال المدة التي حددها طبيبك.</p><p>إذا توقفت فجأة عن تناول زولان&trade;، فقد تُصاب بأعراض مثل التَّعرق وعدم القدرة على النوم والارتعاش والقلق أو الغثيان والقيء. قد يقترح عليك طبيبك خفض الجرعة تدريجيًّا قبل إيقاف العلاج.</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>4. الآثار الجانبية المُحتملة</p><p>&nbsp;</p><p>مثل كافة الأدوية، فقد يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p>أبلغ طبيبك فورًا إذا أصبت بأي من الآثار التالية:</p><p>&bull; حركات غير معتادة (أثر جانبي شائع قد يُؤثر على ما يصل إلى مريض واحد من بين كل 10&nbsp;مرضى) تحدث بشكل أساسي بالوجه أو اللسان.</p><p>&bull; جلطات دموية بالأوردة (أثر جانبي غير شائع قد يؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض) تحدث على وجه الخصوص في الساقين (تتضمن الأعراض: تورم وألم واحمرار في الساق)، والتي قد تنتقل عبر الأوعية الدموية إلى الرئتين مسببة ألمًا في الصدر وصعوبة في التنفس. إذا لاحظت أيًّا من هذه الأعراض، فحاول الحصول على المشورة الطبية على الفور.</p><p>&bull; مزيج من الحمى وتسرع التنفس والتَّعرق وتصلب العضلات والنعاس أو الرغبة في النوم (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة).</p><p>&nbsp;</p><p>آثار جانبية شائعة جدًّا (قد تُؤثر على أكثر من مريض واحد من بين كل 10&nbsp;مرضى) تشمل زيادة الوزن والنعاس وزيادات في مستويات هرمون البرولاكتين في الدَّم. قد يشعر بعض المرضى في المراحل المبكرة من العلاج بدوخة أو إغماء (مع تباطؤ معدل ضربات القلب)، خاصة عند النهوض من وضع الرقود أو الجلوس. عادة ما تنتهي هذه الأعراض من تلقاء نفسها، لكن عليك إبلاغ طبيبك إذا لم تنتهي هذه الأعراض.</p><p>&nbsp;</p><p>آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 10 مرضى) تشمل تغيرات في مستويات بعض خلايا الدم والدهون بالدورة الدموية وزيادات مؤقتة في الإنزيمات الكبدية في بداية العلاج وزيادات في مستوى السكريات في الدَّم والبول وزيادات في مستويات حمض اليوريك وفوسفوكايناز الكرياتين في الدَّم وتكرار الشعور بالجوع والدوخة والشعور بعدم الارتياح وارتعاش عضلي وحركات غير معتادة (خَللُ الحَرَكَة) وإمساك وجفاف الفم وطفح جلدي وفقدان القوة وتعب شديد واحتباس الماء مما يُؤدي إلى تورم اليدين أو الكاحلين أو القدمين وحمى وألم بالمفاصل وخلل بالوظائف الجنسية مثل انخفاض الرغبة الجنسية لدى الذكور والإناث أو اضطرابات بالانتصاب لدى الذكور.</p><p>&nbsp;</p><p>آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض) تشمل فرط الحساسية (مثل: تورم في الفم أو الحلق أو حكة أو طفح جلدي) أو الإصابة بمرض السكري أو تدهور حالة مرض السكري الحالية وغالبًا ما يصاحب ذلك حُماض كيتوني (كيتونات في الدم والبول) أو غيبوبة أو نوبات تشنجية عادة ما تكون مصاحبة لتاريخ من الإصابة بنوبات تشنجية (الصرع) أو تصلب العضلات أو تشنجات (تشمل حركات العينين) أو مشاكل في النطق أو انخفاض معدل ضربات القلب أو حساسية تجاه ضوء الشمس أو نزيف من الأنف أو انتفاخ البطن أو فقدان الذاكرة أو النسيان أو سلس البول أو انخفاض القدرة على التبول أو تساقط الشعر أو انقطاع دورات الطمث أو قلتها أو تغيرات في الصدر لدى الذكور والإناث مثل إفراز غير طبيعي للبن الصدر أو نمو غير طبيعي في الثدي.</p><p>&nbsp;</p><p>آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 1000 مريض) تشمل انخفاض درجة حرارة الجسم الطبيعية، عدم انتظام ضربات القلب وفاة مفاجئة غير معروفة الأسباب والتهاب البنكرياس الذي يسبب ألمًا شديدًا في المعدة وحمى وإعياء ومرض بالكبد يظهر على هيئة اصفرار البشرة والأجزاء البيضاء من العينين ومرض عضلي يظهر على هيئة آلام وأوجاع غير معروفة الأسباب وانتصابًا مؤلمًا و/أو ممتد لفترة طويلة.</p><p>&nbsp;</p><p>آثار جانبية نادرة جدًّا تشمل تفاعلات حساسية خطيرة، مثل الطفح الجلدي الدَّوائي المصحوب بكثرة خلايا اليُوزينِيَّات والأعراض الجهازية (DRESS).&nbsp; يظهر &quot;الطفح الجلدي الدَّوائي المصحوب بكثرة خلايا اليُوزينِيَّات والأعراض الجهازية&quot; أولًا على شكل أعراض شبيهة بأعراض الإنفلونزا مصاحبة بطفح جلدي ثم ينتشر الطفح الجلدي ويصاحبه ارتفاع درجة حرارة الجسم وتضخم العقد اللمفاوية وارتفاع في مستويات إنزيمات الكبد يظهر في فحوصات الدم وارتفاع في نوع من كرات الدم البيضاء (كثرة خلايا اليُوزينِيَّات).</p><p>&nbsp;</p><p>أثناء العلاج بأولانزابين، قد يعاني المرضى كبار السن المصابون بخرف من سكتة دماغية والتهاب رئوي وسلس البول وسقوط على الأرض وتعب شديد و هلاوس بصرية وارتفاع في درجة حرارة الجسم واحمرار الجلد وصعوبة في المشي. تم الإبلاغ عن بعض حالات الوفاة في هذه الفئة المحددة من المرضى.</p><p>&nbsp;</p><p>قد يُؤدي زولان&trade; إلى تدهور أعراض مرض الشلل الرعاش لدى المرضى الذين يعانون منه.</p><p>&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p>إذا ظهرت لديك أية آثار جانبية، تحدث إلى طبيبك أو الممرض(ة) المتابعة لك. بما في ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.</p><p>من خلال إبلاغك عن الآثار الجانبية، يُمكِنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>5. كيفية تخزين زولان&trade;</p><p>&nbsp;</p><p>يُحفظ بعيدًا عن مُتناوَل و مرأى الأطفال.</p><p>يُحفظ في درجة حرارة لا تزيد عن ٠٣ درجة مئوية.</p><p>لا تَستخدِم هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة.</p><p>يحفظ في العبوة الأصلية للحماية من الضوء و الرطوبة.</p><p>يجب عدم التَّخلص من الأدوية عن طريق مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد بحاجة إليها. ستُساعد هذه التَّدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>6. معلومات إضافية</p><p>&nbsp;</p><p>على ماذا يحتوي زولان&trade;؟</p><p>المادة الفعالة هي:</p><p>زولان&trade; 5 ملجم: يحتوي كل قرص مغلف على 5 ملجم من أولانزابين.</p><p>زولان&trade; 10 ملجم: يحتوي كل قرص مغلف على 10 ملجم من أولانزابين.</p><p>المكونات الأخرى هي:</p><p>المحتوى الداخلي: مونوهيدرات اللاكتوز، سليلوز دقيق التَبلّور (في شكل جزيئات بلورية دقيقة)، كروسبوفيدون، ستيرات المغنيسيوم.</p><p>طبقة الغلاف: أوبادري OY-B-28920 [كحول بولي فينيل محلل مائيًّا بشكل جزئي، ثاني أكسيد التيتانيوم (E171)، تلك، صويا الليسثين (E322)، صمغ الزَّانْثان (E415)].</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>ما هو شكل زولان&trade;؟ وما هي محتويات العبوة؟</p><p>زولان&trade; 5 ملجم:</p><p>أقراص مغلفة لونها أبيض مستديرة الشكل، محدبة الوجهين، محفور على أحد جانبيها &quot;JP AB&quot; والجانب الآخر أملس.&nbsp;</p><p>زولان&trade; 10 ملجم:</p><p>أقراص مغلفة لونها أبيض مستديرة الشكل، محدبة الوجهين، محفور على أحد جانبيها &quot;JP 147&quot; و الجانب الآخر أملس.</p><p>&nbsp;</p><p>زولان&trade; أقراص مغلفة متوفرة في أقراص ٥ ملجم و 01 ملجم في علب تحتوي كل علبة على ٠٣ قرص.</p><p>&nbsp;</p><p>قد لا تكون كل العبوات مطروحة فى السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>اسم وعنوان مالك رخصة التسويق و المصنع:</p><p>شركة مصنع جمجوم للأدوية،</p><p>جدة، المملكة العربية السعودية.</p><p>هاتف: 6081111-12-966+&nbsp;&nbsp;&nbsp;&nbsp;</p><p>فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني: www.jamjoompharma.com</p><p>&nbsp;</p><p>للإبلاغ عن أي أثار جانبيه:</p><p>&nbsp;</p><p>&bull; المملكة العربية السعودية:</p><p>- المركز الوطني للتيقظ و السلامة الدوائية</p><p>&nbsp;&nbsp; o فاكس: 7662-205-11-966+</p><p>&nbsp;&nbsp; o للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 20382222-11-966+&nbsp; تحويلة:2317-2356-2353-2354-2334-2340</p><p>&nbsp;&nbsp; o الهاتف المجاني: 8002490000&nbsp;&nbsp;</p><p>&nbsp;&nbsp; o بريد إلكتروني:&nbsp; npc.drug@sfda.gov.sa</p><p>&nbsp;&nbsp; o الموقع الالكتروني: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&bull; دول الخليج الأخرى:</p><p>- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة هذه النشرة في 0٣ /2017. رقم النسخة 01
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zolan 10 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains:
Olanzapine 10 mg
Excipient with known effect: Lactose monohydrate.
For a full list of excipients see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated Tablets
White coloured, round, biconvex, film coated tablets, debossed with 'JP 147' on one side and plain on
other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults<br />Olanzapine is indicated for the treatment of schizophrenia.<br />Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients<br />who have shown an initial treatment response.<br />Olanzapine is indicated for the treatment of moderate to severe manic episode.<br />In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the<br />prevention of recurrence in patients with bipolar disorder (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults<br />Schizophrenia: The recommended starting dose for olanzapine is 10 mg/day.</p><p>Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in<br />combination therapy.<br />Preventing recurrence in bipolar disorder: The recommended starting dose is 10 mg/day. For patients<br />who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing<br />recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, olanzapine<br />treatment should be continued (with dose optimisation as needed), with supplementary therapy to<br />treat mood symptoms, as clinically indicated.<br />During treatment for schizophrenia, manic episode, and recurrence prevention in bipolar disorder,<br />daily dosage may subsequently be adjusted on the basis of individual clinical status within the range<br />5-20 mg/day. An increase to a dose greater than the recommended starting dose is advised only after<br />appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours.<br />Olanzapine can be given without regard for meals, as absorption is not affected by food. Gradual<br />tapering of the dose should be considered when discontinuing olanzapine.</p><p>Special populations<br />Elderly<br />A lower starting dose (5 mg/day) is not routinely indicated but should be considered for those 65 and<br />over when clinical factors warrant.<br />Renal and/or hepatic impairment<br />A lower starting dose (5 mg) should be considered for such patients. In cases of moderate hepatic<br />insufficiency (cirrhosis, Child-Pugh class A or B), the starting dose should be 5 mg and only<br />increased with caution.</p><p>Smokers<br />The starting dose and dose range need not be routinely altered for non-smokers relative to smokers.<br />The metabolism of olanzapine may be induced by smoking. Clinical monitoring is recommended and<br />an increase of olanzapine dose may be considered if necessary.<br />When more than one factor is present which might result in slower metabolism (female gender,<br />geriatric age, non-smoking status), consideration should be given to decreasing the starting dose.<br />Dose escalation, when indicated, should be conservative in such patients.</p><p>In cases where dose increments of 2.5 mg are considered necessary, Olanzapine coated tablets should<br />be used.<br />Paediatric population<br />Olanzapine is not recommended for use in children and adolescents below 18 years of age due to a<br />lack of data on safety and efficacy. A greater magnitude of weight gain, lipid and prolactin alterations<br />has been reported in short-term studies of adolescent patients than in studies of adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Patients with known risk of narrow-angle glaucoma.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days<br />to some weeks. Patients should be closely monitored during this period.<br />Dementia-related psychosis and/or behavioural disturbances<br />Olanzapine is not recommended for use in patients with dementia-related psychosis and/or<br />behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.<br />In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with<br />dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence<br />of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs. 1.5%,<br />respectively). The higher incidence of death was not associated with olanzapine dose (mean daily<br />dose 4.4 mg) or duration of treatment. Risk factors that may predispose this patient population to<br />increased mortality include age &gt; 65 years, dysphagia, sedation, malnutrition and dehydration,<br />pulmonary conditions (e.g., pneumonia, with or without aspiration), or concomitant use of<br />benzodiazepines. However, the incidence of death was higher in olanzapine-treated than in placebotreated<br />patients independent of these risk factors.<br />In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischaemic<br />attack), including fatalities, were reported. There was a 3-fold increase in CVAE in patients treated<br />with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively). All</p><p>olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre-existing<br />risk factors. Age &gt; 75 years and vascular/mixed type dementia were identified as risk factors for<br />CVAE in association with olanzapine treatment. The efficacy of olanzapine was not established in<br />these trials.<br />Parkinson&#39;s disease<br />The use of olanzapine in the treatment of dopamine agonist associated psychosis in patients with<br />Parkinson&#39;s disease is not recommended. In clinical trials, worsening of Parkinsonian<br />symptomatology and hallucinations were reported very commonly and more frequently than with<br />placebo and olanzapine was not more effective than placebo in the treatment of psychotic symptoms.<br />In these trials, patients were initially required to be stable on the lowest effective dose of anti-<br />Parkinsonian medicinal products (dopamine agonist) and to remain on the same anti-Parkinsonian<br />medicinal products and dosages throughout the study. Olanzapine was started at 2.5 mg/day and<br />titrated to a maximum of 15 mg/day based on investigator judgement.</p><p>Neuroleptic Malignant Syndrome (NMS)<br />NMS is a potentially life-threatening condition associated with antipsychotic medicinal products.<br />Rare cases reported as NMS have also been received in association with olanzapine. Clinical<br />manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of<br />autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac<br />dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria<br />(rhabdomyolysis), and acute renal failure. If a patient develops signs and symptoms indicative of<br />NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all<br />antipsychotic medicines, including olanzapine must be discontinued.<br />Hyperglycaemia and diabetes<br />Hyperglycaemia and/or development or exacerbation of diabetes, occasionally associated with<br />ketoacidosis or coma, has been reported uncommonly, including some fatal cases (see section 4.8). In<br />some cases, a prior increase in body weight has been reported, which may be a predisposing factor.<br />Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines, e.g.</p><p>measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually<br />thereafter.<br />Lipid alterations<br />Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebocontrolled<br />clinical trials. Lipid alterations should be managed as clinically appropriate, particularly in<br />dyslipidemic patients and in patients with risk factors for the development of lipids disorders.<br />Anticholinergic activity<br />While olanzapine demonstrated anticholinergic activity in vitro, experience during the clinical trials<br />revealed a low incidence of related events. However, as clinical experience with olanzapine in<br />patients with concomitant illness is limited, caution is advised when prescribing for patients with<br />prostatic hypertrophy, or paralytic ileus and related conditions.</p><p>Hepatic function<br />Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen<br />commonly, especially in early treatment. Caution should be exercised and follow-up organised in<br />patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment,<br />in patients with pre-existing conditions associated with limited hepatic functional reserve, and in<br />patients who are being treated with potentially hepatotoxic medicines. In cases where hepatitis<br />(including hepatocellular, cholestatic or mixed liver injury) has been diagnosed, olanzapine treatment<br />should be discontinued.<br />Neutropenia<br />Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in<br />patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced<br />bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant<br />illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with<br />myeloproliferative disease. Neutropenia has been reported commonly when olanzapine and valproate<br />are used concomitantly (see section 4.8).</p><p>Discontinuation of treatment<br />Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported<br />rarely (&ge; 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.<br />QT interval<br />In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] &ge; 500<br />milliseconds [msec] at any time post-baseline in patients with baseline QTcF &lt; 500 msec) were<br />uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in<br />associated cardiac events compared to placebo. However, caution should be exercised when<br />olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in<br />patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia<br />or hypomagnesaemia.<br />Thromboembolism<br />Temporal association of olanzapine treatment and venous thromboembolism has been reported<br />uncommonly (&ge; 0.1% and &lt; 1%). A causal relationship between the occurrence of venous<br />thromboembolism and treatment with olanzapine has not been established. However, since patients<br />with schizophrenia often present with acquired risk factors for venous thromboembolism, all possible<br />risk factors of VTE e.g., immobilisation of patients, should be identified and preventive measures<br />undertaken.</p><p>General CNS activity<br />Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination<br />with other centrally acting medicines and alcohol. As it exhibits in vitro dopamine antagonism,<br />olanzapine may antagonise the effects of direct and indirect dopamine agonists.<br />Seizures<br />Olanzapine should be used cautiously in patients who have a history of seizures or are subject to<br />factors which may lower the seizure threshold. Seizures have been reported to occur uncommonly in<br />patients when treated with olanzapine. In most of these cases, a history of seizures or risk factors for<br />seizures were reported.</p><p>Tardive dyskinesia<br />In comparator studies of one year or less duration, olanzapine was associated with a statistically<br />significant lower incidence of treatment-emergent dyskinesia. However, the risk of tardive dyskinesia<br />increases with long-term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in<br />a patient on olanzapine, a dose reduction or discontinuation should be considered. These symptoms<br />can temporally deteriorate or even arise after discontinuation of treatment.<br />Postural hypotension<br />Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials. It is<br />recommended that blood pressure is measured periodically in patients over 65 years.<br />Sudden cardiac death<br />In postmarketing reports with olanzapine, the event of sudden cardiac death has been reported in<br />patients with olanzapine. In a retrospective observational cohort study, the risk of presumed sudden<br />cardiac death in patients treated with olanzapine was approximately twice the risk in patients not<br />using antipsychotics. In the study, the risk of olanzapine was comparable to the risk of atypical<br />antipsychotics included in a pooled analysis.</p><p>Paediatric population<br />Olanzapine is not indicated for use in the treatment of children and adolescents. Studies in patients<br />aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic<br />parameters and increases in prolactin levels.<br />Lactose<br />Olanzapine tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the<br />Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.<br />Potential interactions affecting olanzapine<br />Since olanzapine is metabolised by CYP1A2, substances that can specifically induce or inhibit this<br />isoenzyme may affect the pharmacokinetics of olanzapine.<br />Induction of CYP1A2<br />The metabolism of olanzapine may be induced by smoking and carbamazepine, which may lead to<br />reduced olanzapine concentrations. Only slight to moderate increase in olanzapine clearance has been<br />observed. The clinical consequences are likely to be limited, but clinical monitoring is recommended<br />and an increase of olanzapine dose may be considered if necessary (see section 4.2).<br />Inhibition of CYP1A2<br />Fluvoxamine, a specific CYP1A2 inhibitor, has been shown to significantly inhibit the metabolism of<br />olanzapine. The mean increase in olanzapine Cmax following fluvoxamine was 54% in female nonsmokers<br />and 77% in male smokers. The mean increase in olanzapine AUC was 52% and 108%,<br />respectively. A lower starting dose of olanzapine should be considered in patients who are using<br />fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin. A decrease in the dose of<br />olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.<br />Decreased bioavailability<br />Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60% and should be taken at<br />least 2 hours before or after olanzapine.<br />Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have<br />not been found to significantly affect the pharmacokinetics of olanzapine.</p><p>Potential for olanzapine to affect other medicinal products<br />Olanzapine may antagonise the effects of direct and indirect dopamine agonists.<br />Olanzapine does not inhibit the main CYP450 isoenzymes in vitro (e.g., 1A2, 2D6, 2C9, 2C19, 3A4).<br />Thus, no particular interaction is expected, as verified through in vivo studies, where no inhibition of<br />metabolism of the following active substances was found: tricyclic antidepressant (representing<br />mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2), or diazepam (CYP3A4 and<br />2C19).<br />Olanzapine showed no interaction when co-administered with lithium or biperiden.<br />Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is<br />required after the introduction of concomitant olanzapine.<br />General CNS activity<br />Caution should be exercised in patients who consume alcohol or receive medicinal products that can<br />cause central nervous system depression.<br />The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with<br />Parkinson&#39;s disease and dementia is not recommended.<br />QTc interval<br />Caution should be used if olanzapine is being administered concomitantly with medicinal products<br />known to increase QTc interval.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Category C<br />Pregnancy<br />There are no adequate and well-controlled studies in pregnant women. Patients should be advised to<br />notify their physician if they become pregnant or intend to become pregnant during treatment with<br />olanzapine. Nevertheless, because human experience is limited, olanzapine should be used in<br />pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>New born infants exposed to antipsychotics (including olanzapine) during the third trimester of<br />pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that<br />may vary in severity and duration following delivery. There have been reports of agitation,<br />hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently,<br />newborns should be monitored carefully.<br />Breast-feeding<br />In a study in breast-feeding, healthy women, olanzapine was excreted in breast milk. Mean infant<br />exposure (mg/kg) at steady-state was estimated to be 1.8% of the maternal olanzapine dose (mg/kg).<br />Patients should be advised not to breast-feed an infant if they are taking olanzapine.<br />Fertility<br />Effects on fertility are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Because<br />olanzapine may cause somnolence and dizziness, patients should be cautioned about operating<br />machinery, including motor vehicles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Adults<br />The most frequently (seen in &ge; 1% of patients) reported adverse reactions associated with the use of<br />olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin,<br />cholesterol, glucose and triglyceride levels. glucosuria, increased appetite, dizziness, akathisia,<br />parkinsonism, leukopenia, neutropenia, dyskinesia, orthostatic hypotension, anticholinergic effects,<br />transient asymptomatic elevations of hepatic aminotransferases, rash, asthenia, fatigue, pyrexia,<br />arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high<br />creatine phosphokinase and oedema.</p><p>Tabulated list of adverse reactions<br />The following table lists the adverse reactions and laboratory investigations observed from<br />spontaneous reporting and in clinical trials. Within each frequency grouping, adverse reactions are<br />presented in order of decreasing seriousness. The frequency terms listed are defined as follows: Very<br />common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to<br />&lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the data available).</p><p><img alt="" src="data:image/png;base64,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" /></p><p><img alt="" src="data:image/png;base64,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" /></p><p><img alt="" src="data:image/png;base64,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" /></p><p><img alt="" src="data:image/png;base64,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" /></p><p>1Clinically significant weight gain was observed across all baseline Body Mass Index (BMI)<br />categories. Following short-term treatment (median duration 47 days), weight gain &ge; 7% of baseline<br />body weight was very common (22.2%); &ge; 15% was common (4.2%); and &ge; 25% was uncommon<br />(0.8%). Patients gaining &ge; 7%, &ge; 15% and &ge; 25% of their baseline body weight with long-term<br />exposure (at least 48 weeks) were very common (64.4%, 31.7% and 12.3% respectively).<br />2Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were<br />greater in patients without evidence of lipid dysregulation at baseline.<br />3Observed for fasting normal levels at baseline (&lt; 5.17 mmol/l) which increased to high (&ge; 6.2<br />mmol/l). Changes in total fasting cholesterol levels from borderline at baseline (&ge; 5.17 - &lt; 6.2 mmol/l)<br />to high (&ge; 6.2 mmol/l) were very common.<br />4Observed for fasting normal levels at baseline (&lt; 5.56 mmol/l) which increased to high (&ge; 7 mmol/l).<br />Changes in fasting glucose from borderline at baseline (&ge; 5.56 - &lt; 7 mmol/l) to high (&ge; 7 mmol/l)<br />were very common.<br />5Observed for fasting normal levels at baseline (&lt; 1.69 mmol/l) which increased to high (&ge; 2.26<br />mmol/l). Changes in fasting triglycerides from borderline at baseline (&ge; 1.69 mmol/l - &lt; 2.26 mmol/l)<br />to high (&ge; 2.26 mmol/l) were very common.<br />6In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was<br />numerically higher, but not statistically significantly different from placebo. Olanzapine-treated<br />patients had a lower incidence of Parkinsonism, akathisia and dystonia compared with titrated doses<br />of haloperidol. In the absence of detailed information on the pre-existing history of individual acute</p><p>and tardive extrapyramidal movement disorders, it cannot be concluded at present that olanzapine<br />produces less tardive dyskinesia and/or other tardive extrapyramidal syndromes.<br />7Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been<br />reported when olanzapine is stopped abruptly.<br />8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of<br />normal range in approximately 30% of olanzapine-treated patients with normal baseline prolactin<br />value. In the majority of these patients the elevations were generally mild, and remained below two<br />times the upper limit of normal range.<br />9 Adverse event identified from clinical trials in the Olanzapine Integrated Database.<br />10 As assessed by measured values from clinical trials in the Olanzapine Integrated Database.<br />11 Adverse event identified from spontaneous post-marketing reporting with frequency determined<br />utilising the Olanzapine Integrated Database.<br />12 Adverse event identified from spontaneous post-marketing reporting with frequency estimated at<br />the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database.<br />Long-term exposure (at least 48 weeks)<br />The proportion of patients who had adverse, clinically significant changes in weight gain, glucose,<br />total/LDL/HDL cholesterol or triglycerides increased over time. In adult patients who completed 9-12<br />months of therapy, the rate of increase in mean blood glucose slowed after approximately 6 months.<br />Additional information on special populations<br />In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher<br />incidence of death and cerebrovascular adverse reactions compared to placebo. Very common adverse<br />reactions associated with the use of olanzapine in this patient group were abnormal gait and falls.<br />Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary<br />incontinence were observed commonly.<br />In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with<br />Parkinson&#39;s disease, worsening of Parkinsonian symptomatology and hallucinations were reported<br />very commonly and more frequently than with placebo.<br />In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine<br />resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma</p><p>valproate levels. Olanzapine administered with lithium or valproate resulted in increased levels<br />(&ge;10%) of tremor, dry mouth, increased appetite, and weight gain. Speech disorder was also reported<br />commonly. During treatment with olanzapine in combination with lithium or divalproex, an increase<br />of &ge; 7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6<br />weeks). Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with<br />bipolar disorder was associated with an increase of &ge;7% from baseline body weight in 39.9% of<br />patients.<br />Paediatric population<br />Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.<br />Although no clinical studies designed to compare adolescents to adults have been conducted, data<br />from the adolescent trials were compared to those of the adult trials.<br />The following table summarises the adverse reactions reported with a greater frequency in adolescent<br />patients (aged 13-17 years) than in adult patients or adverse reactions only identified during shortterm<br />clinical trials in adolescent patients. Clinically significant weight gain (&ge; 7%) appears to occur<br />more frequently in the adolescent population compared to adults with comparable exposures. The<br />magnitude of weight gain and the proportion of adolescent patients who had clinically significant<br />weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />The frequency terms listed are defined as follows: Very common (&ge; 1/10), common (&ge; 1/100 to &lt;<br />1/10).</p><p><img alt="" src="data:image/png;base64,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" /></p><p><img alt="" src="data:image/png;base64,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" /></p><p>13Following short-term treatment (median duration 22 days), weight gain &ge; 7% of baseline body<br />weight (kg) was very common (40.6%); &ge; 15% of baseline body weight was common (7.1%) and &ge;<br />25% was common (2.5%). With long-term exposure (at least 24 weeks), 89.4% gained &ge; 7%, 55.3%<br />gained &ge; 15% and 29.1% gained &ge; 25% of their baseline body weight.<br />14Observed for fasting normal levels at baseline (&lt; 1.016 mmol/l) which increased to high (&ge; 1.467<br />mmol/l) and changes in fasting triglycerides from borderline at baseline (&ge; 1.016 mmol/l - &lt; 1.467<br />mmol/l) to high (&ge; 1.467 mmol/l).<br />15Changes in total fasting cholesterol levels from normal at baseline (&lt; 4.39 mmol/l) to high (&ge; 5.17<br />mmol/l) were observed commonly. Changes in total fasting cholesterol levels from borderline at<br />baseline (&ge; 4.39 - &lt; 5.17 mmol/l) to high (&ge; 5.17 mmol/l) were very common.<br />16Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs and symptoms<br />Very common symptoms in overdose (&gt; 10% incidence) include tachycardia,<br />agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of<br />consciousness ranging from sedation to coma.<br />Other medically significant sequelae of overdose include delirium, convulsion, coma, possible<br />neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension,<br />cardiac arrhythmias (&lt;2% of overdose cases), and cardiopulmonary arrest. Fatal outcomes have been<br />reported for acute overdoses as low as 450 mg, but survival has also been reported following acute<br />overdose of approximately 2 g of oral olanzapine.<br />Management<br />There is no specific antidote for olanzapine. Induction of emesis is not recommended. Standard<br />procedures for management of overdose may be indicated (i.e., gastric lavage, administration of<br />activated charcoal). The concomitant administration of activated charcoal was shown to reduce the<br />oral bioavailability of olanzapine by 50 to 60%.<br />Symptomatic treatment and monitoring of vital organ function should be instituted according to<br />clinical presentation, including treatment of hypotension and circulatory collapse and support of<br />respiratory function. Do not use epinephrine, dopamine, or other sympathomimetic agents with betaagonist<br />activity, since beta stimulation may worsen hypotension. Cardiovascular monitoring is<br />necessary to detect possible arrhythmias. Close medical supervision and monitoring should continue<br />until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>psycholeptics, diazepines, oxazepines, thiazepines and oxepines,<br />ATC code N05A H03<br />Olanzapine is an antipsychotic, antimanic, and mood stabilising agent that demonstrates a broad<br />pharmacologic profile across a number of receptor systems.<br />In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki &lt;100nM) for serotonin<br />5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5;<br />&alpha;1 adrenergic; and histamine H1 receptors. Animal behavioural studies with olanzapine indicated<br />5HT, dopamine, and cholinergic antagonism, consistent with the receptor-binding profile. Olanzapine<br />demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater<br />5HT2 than D2 activity in in vivo models. Electrophysiological studies demonstrated that olanzapine<br />selectively reduced the firing of mesolimbic (A10) dopaminergic neurons, while having little effect on<br />the striatal (A9) pathways involved in motor function. Olanzapine reduced a conditioned avoidance<br />response, a test indicative of antipsychotic activity, at doses below those producing catalepsy, an<br />effect indicative of motor side-effects. Unlike some other antipsychotic agents, olanzapine increases<br />responding in an &#39;anxiolytic&#39; test.<br />In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers,<br />olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy. In addition, a Single<br />Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed<br />that olanzapine-responsive patients had lower striatal D2occupancy than some other antipsychoticand<br />risperidone-responsive patients, while being comparable to clozapine-responsive patients.<br />Clinical efficacy<br />In two of two placebo- and two of three comparator-controlled trials with over 2,900 schizophrenic<br />patients presenting with both positive and negative symptoms, olanzapine was associated with<br />statistically significantly greater improvements in negative as well as positive symptoms.<br />In a multinational, double-blind, comparative study of schizophrenia, schizoaffective and related<br />disorders, which included 1,481 patients with varying degrees of associated depressive symptoms<br />(baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective</p><p>secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant<br />improvement (P = 0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).<br />In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior<br />efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3<br />weeks. Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the<br />proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks. In a<br />co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition<br />of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in<br />symptoms of mania than lithium or valproate monotherapy after 6 weeks.<br />In a 12 month recurrence prevention study in manic episode patients who achieved remission on<br />olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically<br />significant superiority over placebo on the primary endpoint of bipolar recurrence. Olanzapine also<br />showed a statistically significant advantage over placebo in terms of preventing either recurrence into<br />mania or recurrence into depression.<br />In a second 12 month recurrence prevention study in manic episode patients who achieved remission<br />with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium<br />alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar<br />recurrence (olanzapine 30.0%, lithium 38.3%; P = 0.055).<br />In an 18 month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a<br />mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was<br />not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence,<br />defined according to syndromic (diagnostic) criteria.<br />Paediatric population<br />Controlled efficacy data in adolescents (ages 13 to 17 years) are limited to short term studies in<br />schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than<br />200 adolescents. Olanzapine was used as a flexible dose starting with 2.5 and ranging up to 20<br />mg/day. During treatment with olanzapine, adolescents gained significantly more weight compared<br />with adults. The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and<br />prolactin (see sections 4.4 and 4.8) were greater in adolescents than in adults. There are no controlled<br />data on maintenance of effect or long term safety (see sections 4.4 and 4.8). Information on long term<br />safety is primarily limited to open-label, uncontrolled data.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5<br />to 8 hours. The absorption is not affected by food. Absolute oral bioavailability relative to intravenous<br />administration has not been determined.<br />Distribution<br />The plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to<br />about 1000 ng/ml. Olanzapine is bound predominantly to albumin and &alpha;1-acid-glycoprotein.<br />Biotransformation<br />Olanzapine is metabolised in the liver by conjugative and oxidative pathways. The major circulating<br />metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier. Cytochromes P450-<br />CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl<br />metabolites; both exhibited significantly less in vivo pharmacological activity than olanzapine in<br />animal studies. The predominant pharmacologic activity is from the parent, olanzapine.<br />Elimination<br />After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects<br />varied on the basis of age and gender.<br />In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was<br />prolonged (51.8 versus 33.8 hours) and the clearance was reduced (17.5 versus 18.2 l/hr). The<br />pharmacokinetic variability observed in the elderly is within the range for the non-elderly. In 44<br />patients with schizophrenia &gt;65 years of age, dosing from 5 to 20 mg/day was not associated with any<br />distinguishing profile of adverse events.<br />In female versus male subjects, the mean elimination half-life was somewhat prolonged (36.7 versus<br />32.3 hours) and the clearance was reduced (18.9 versus 27.3 l/hr). However, olanzapine (5-20 mg)<br />demonstrated a comparable safety profile in female (n = 467) as in male patients (n = 869).<br />Renal impairment<br />In renally impaired patients (creatinine clearance &lt;10ml/min) versus healthy subjects, there was no<br />significant difference in mean elimination half-life (37.7 versus 32.4 hours) or clearance (21.2 versus<br />25.0 l/hr). A mass balance study showed that approximately 57% of radiolabelled olanzapine<br />appeared in urine, principally as metabolites.</p><p>Smokers<br />In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hours) was<br />prolonged and clearance (18.0 l/hr) was reduced analogous to non-smoking healthy subjects (48.8<br />hours and 14.1 l/hr, respectively).<br />In non-smoking versus smoking subjects (males and females), the mean elimination half-life was<br />prolonged (38.6 versus 30.4 hours) and the clearance was reduced (18.6 versus 27.7 l/hr).<br />The plasma clearance of olanzapine is lower in elderly versus young subjects, in females versus<br />males, and in non-smokers versus smokers. However, the magnitude of the impact of age, gender, or<br />smoking on olanzapine clearance and half-life is small in comparison to the overall variability<br />between individuals.<br />In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the<br />pharmacokinetic parameters among the three populations.<br />Paediatric population<br />Adolescents (ages 13 to 17 years): The pharmacokinetics of olanzapine are similar between<br />adolescents and adults. In clinical studies, the average olanzapine exposure was approximately 27%<br />higher in adolescents. Demographic differences between the adolescents and adults include a lower<br />average body weight and fewer adolescents were smokers. Such factors possibly contribute to the<br />higher average exposure observed in adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute (single-dose) toxicity<br />Signs of oral toxicity in rodents were characteristic of potent neuroleptic compounds: hypoactivity,<br />coma, tremors, clonic convulsions, salivation, and depressed weight gain. The median lethal doses<br />were approximately 210 mg/kg (mice) and 175 mg/kg (rats). Dogs tolerated single oral doses up to<br />100 mg/kg without mortality. Clinical signs included sedation, ataxia, tremors, increased heart rate,<br />laboured respiration, miosis, and anorexia. In monkeys, single oral doses up to 100 mg/kg resulted in<br />prostration and, at higher doses, semi-consciousness.</p><p>Repeated-dose toxicity<br />In studies up to 3 months duration in mice and up to 1 year in rats and dogs, the predominant effects<br />were CNS depression, anticholinergic effects, and peripheral haematological disorders. Tolerance<br />developed to the CNS depression. Growth parameters were decreased at high doses. Reversible<br />effects consistent with elevated prolactin in rats included decreased weights of ovaries and uterus and<br />morphologic changes in vaginal epithelium and in mammary gland.<br />Haematologic toxicity<br />Effects on haematology parameters were found in each species, including dose-related reductions in<br />circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however,<br />no evidence of bone marrow cytotoxicity was found. Reversible neutropenia, thrombocytopenia, or<br />anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [area<br />under the curve] is 12- to 15-fold greater than that of a man given a 12 mg dose). In cytopenic dogs,<br />there were no adverse effects on progenitor and proliferating cells in the bone marrow.<br />Reproductive toxicity<br />Olanzapine had no teratogenic effects. Sedation affected mating performance of male rats. Oestrous<br />cycles were affected at doses of 1.1 mg/kg (3-times the maximum human dose) and reproduction<br />parameters were influenced in rats given 3 mg/kg (9-times the maximum human dose). In the<br />offspring of rats given olanzapine, delays in foetal development and transient decreases in offspring<br />activity levels were seen.<br />Mutagenicity<br />Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included<br />bacterial mutation tests and in vitro and in vivo mammalian tests.<br />Carcinogenicity<br />Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate<br />Lactose Monohydrate (Super tab 11 SD)<br />Microcrystalline Cellulose (Avicel PH112)<br />Crospovidone (Polyplasdone XL-10)<br />Magnesium Stearate<br />Opadry -OY-B-28920<br />Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu blister pack<br />Pack sizes: 3 X 10&rsquo;s Blister Pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442,
Kingdom of Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May-2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>